[ad_1]
This Proposed Pharma Grade Version of Tauri-Gum™ is Being
Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy
Treatment
NEW YORK, NY – 
(OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating,
diversified life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon,
Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives,
today announced the resumption of clinical development efforts, concerning its
proposed “Anti-Nausea” pharmaceutical grade version of Tauri-Gum™. The Company expects to issue a material
update to shareholders, within the near term (concerning the resumption of this
Pharmaceutical Development Work).
The delivery
system for this proposed Pharmaceutical version is a modified version
(substantially higher concentration of CBD) of the existing “Tauri-Gum™”
chewing gum formulation based on continued research and development.
On March 18,
2020 the Company announced that it had filed a Provisional U.S. Patent covering
its Pharmaceutical grade version of Tauri-Gum™. This patent application,
filed with the United States Patent & Trademark Office (“U.S.P.T.O.”), is
titled: “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF
TREATMENT.”
U.S. Provisional Patent Application No. 62/990,709
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major business activities
and initiatives. The company manufactures and distributes several
proprietary retail products and product lines, mainly focused on the
Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™, consists of a
proprietary supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange,
Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant)
& (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear
Bellini). The Company’s commercialization strategy consists of a
broad array of retail customers, distributors, and a fast-growing E-Commerce
business segment (E-Commerce website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to the
development of a Pharmaceutical grade version of Tauri-Gum™, for nausea
regulation (specifically designed to help patients that are subjected to
ongoing chemotherapy treatment). On March 18, 2020, the Company announced
that it filed a provisional U.S. patent application covering its pharmaceutical
grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O.
is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF
TREATMENT”. The second one relates to a collaboration agreement with Aegea
Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel
Coronavirus (COVID-19) test with superior sensitivity and
selectivity.
On October 6, 2020, the Company announced that it has been
approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)
On October 7, 2020 the Company disclosed a Strategic Alliance
with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of
Christopher “The Notorious B.I.G.” Wallace.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in LaGrangeville,
New York.
DISCLAIMER — Forward-Looking Statements
This press release contains certain “forward-looking
statements” as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning future events.
These forward-looking statements are often indicated by using words such as
“may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as well as the
attainment of certain corporate goals and milestones. Forward-looking statements
are based on present circumstances and on management’s present beliefs with
respect to events that have not occurred, that may not occur, or that may occur
with different consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed in forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of general economic
and business conditions, the ability to successfully develop and market
products, consumer and business consumption habits, the ability to consummate
successful acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no control. Many of
these risks and uncertainties are discussed in greater detail in the “Risk
Factors” section of Tauriga’s Form 10-K and other filings made from time to
time with the Securities and Exchange Commission. Such forward-looking
statements are made only as of the date of this release, and Tauriga assumes no
obligation to update forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these forward-looking
statements.
Contact:
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email:
sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website:
www.tauriga.com
E-Commerce Website: www.taurigum.com
[ad_2]